Arbutus BiopharmaABUS
Market Cap: $859M
About: Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Employees: 73
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
761% more call options, than puts
Call options by funds: $11M | Put options by funds: $1.28M
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
63% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 30
25% more capital invested
Capital invested by funds: $237M [Q1] → $297M (+$60.3M) [Q2]
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
10% more funds holding
Funds holding: 116 [Q1] → 128 (+12) [Q2]
0.13% less ownership
Funds ownership: 51.19% [Q1] → 51.06% (-0.13%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Jefferies Dennis Ding 0% 1-year accuracy 0 / 1 met price target | 54%upside $7 | Buy Maintained | 5 Sept 2024 |
JMP Securities Roy Buchanan 25% 1-year accuracy 4 / 16 met price target | 10%upside $5 | Market Outperform Maintained | 2 Aug 2024 |